Table 3 The initial dose and dose adjustment of thrombopoietin-receptor agonists.
Study ID | Medication | TPO-RA Initial dose | Dose adjustment | Follow-up during double-blind phase |
|---|---|---|---|---|
Bussel 2015 | Eltrombopag | 1–5years: 1.5 mg/kg/day (0·8 mg/kg once per day for east Asian patients). 6–11years: ≥27 kg: 50 mg/day or (25 mg/day for east Asian patients); <27 kg: 25 mg/day (12.5 mg/day for east Asian patient). 12–17years: 37.5 mg/day, orally. | Decreased dose by 12·5 mg/day if PC > 200 × 109/L. Increased dose by 12·5 mg/day if PC < 50 × 109/L, max 75 mg/d or 2 mg/kg/d. Interrupted treatment if PC > 400 × 109/L. | 7 weeks |
Grainger 2015 | Eltrombopag | 1–5years: 1.2 mg/kg/day (0.8 mg/kg/day for east Asian patients). doses were adjusted based on platelet counts. 6–17yeas: ≥27 kg: 50 mg/day (25 mg/day for east Asian patients); <27 kg: 37·5 mg/day (25 mg/day for east Asian patients). | Doses were adjusted based on PC: Decreased dose if PC > 200 × 109/L. Interrupted treatment if PC > 400 × 109/L. | 13 weeks |
Bussel 2011 | Romiplostim | 1 μg/kg, once weekly. | Dose was adjusted to achieve target PC of 50 to 250 × 109/L. | 12 weeks |
Tarantino 2016 | Romiplostim | 1 μg/kg, once weekly. | Dose was adjusted to achieve target paltelet counts of 50 to 200 × 109/L. | 24 weeks |
Elalfy 2011 | Romiplostim | 1 μg/kg, once weekly. | Doses were escalated to 5 μg/kg and then tapered. | 18 weeks |
